ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2

World Health Organization Seroepidemiology Technical Working Group

doi:10.1111/irv.12870

ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2

World Health Organization Seroepidemiology Technical Working Group

Virology

World Health Organization
Centers for Disease Control and Prevention
Institut Pasteur Paris
University of Oxford
UK Health Security Agency
Charité – Universitätsmedizin Berlin
The University of Hong Kong

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

145 Downloads (Pure)

Abstract

Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies—SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design.

Original language	English
Pages (from-to)	561-568
Number of pages	8
Journal	Influenza and other Respiratory Viruses
Volume	15
Issue number	5
Early online date	26 Jun 2021
DOIs	https://doi.org/10.1111/irv.12870
Publication status	Published - 1 Sept 2021

Bibliographical note

Funding Information:
The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors

Publisher Copyright:
© 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/irv.12870Licence: CC BY

Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2Final published version, 233 KBLicence: CC BY

Cite this

@article{5deffff1840c43f8a08d801be83f52c2,

title = "ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2",

abstract = "Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies{\textemdash}SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design.",

author = "\{World Health Organization Seroepidemiology Technical Working Group\} and \{Van Kerkhove\}, \{Maria D.\} and Rebecca Grant and Lorenzo Subissi and Marta Valenciano and Ketevan Glonti and Isabel Bergeri and Polina Brangel and \{Le Polain\}, Olivier and Hannah Lewis and Anthony Nardone and Richard Pebody and Tasnim Azim and Pushpa Wijesinghe and \{Al Ariqi\}, Lubna and Le, \{Linh Vi\} and Joseph Okeibunor and Andrea Vicari and Hamida, \{Amen Ben\} and Venkatachalam Udhayakumar and Kathleen Gallagher and Vincent Richard and Rahul Arora and Niklas Bobrovitz and Maria Zambon and Christian Drosten and Marion Koopmans and Malik Peiris",

note = "Funding Information: The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors Publisher Copyright: {\textcopyright} 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley \& Sons Ltd.",

year = "2021",

month = sep,

day = "1",

doi = "10.1111/irv.12870",

language = "English",

volume = "15",

pages = "561--568",

journal = "Influenza and other Respiratory Viruses",

issn = "1750-2640",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "5",

}

TY - JOUR

T1 - ROSES-S

T2 - Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2

AU - World Health Organization Seroepidemiology Technical Working Group

AU - Van Kerkhove, Maria D.

AU - Grant, Rebecca

AU - Subissi, Lorenzo

AU - Valenciano, Marta

AU - Glonti, Ketevan

AU - Bergeri, Isabel

AU - Brangel, Polina

AU - Le Polain, Olivier

AU - Lewis, Hannah

AU - Nardone, Anthony

AU - Pebody, Richard

AU - Azim, Tasnim

AU - Wijesinghe, Pushpa

AU - Al Ariqi, Lubna

AU - Le, Linh Vi

AU - Okeibunor, Joseph

AU - Vicari, Andrea

AU - Hamida, Amen Ben

AU - Udhayakumar, Venkatachalam

AU - Gallagher, Kathleen

AU - Richard, Vincent

AU - Arora, Rahul

AU - Bobrovitz, Niklas

AU - Zambon, Maria

AU - Drosten, Christian

AU - Koopmans, Marion

AU - Peiris, Malik

N1 - Funding Information: The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors Publisher Copyright: © 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies—SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design.

AB - Well-designed population-based seroepidemiologic studies can be used to refine estimates of infection severity and transmission, and are therefore an important component of epidemic surveillance. However, the interpretation of the results of seroepidemiologic studies for SARS-CoV-2 has been hampered to date principally by heterogeneity in the quality of the reporting of the results of the study and a lack of standardized methods and reporting. We provide here the ROSES-S: Reporting of Seroepidemiologic studies—SARS-CoV-2. This is an updated checklist of 22 items that should be included in the reporting of all SARS-CoV-2 seroepidemiologic studies, irrespective of study design.

UR - https://www.scopus.com/pages/publications/85108529666

U2 - 10.1111/irv.12870

DO - 10.1111/irv.12870

M3 - Article

C2 - 34173715

AN - SCOPUS:85108529666

SN - 1750-2640

VL - 15

SP - 561

EP - 568

JO - Influenza and other Respiratory Viruses

JF - Influenza and other Respiratory Viruses

IS - 5

ER -

ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this